Research Paper Volume 13, Issue 16 pp 20661—20683

METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas

METTL21B is correlated with immune checkpoints and tumor mutation burden. (A) Correlation between expression of 8 immune checkpoints and METTL21B. The effects of CD274 (B), CTLA4 (C), HAVCR2 (D), LAG3 (E), PDCD1 (F), PDCD1LG2 (G) and SIGLEC15 (H) on prognosis of patients with LGG. (I) The correlation between expression of METTL21B and tumor mutation burden in LGG.

Figure 8. METTL21B is correlated with immune checkpoints and tumor mutation burden. (A) Correlation between expression of 8 immune checkpoints and METTL21B. The effects of CD274 (B), CTLA4 (C), HAVCR2 (D), LAG3 (E), PDCD1 (F), PDCD1LG2 (G) and SIGLEC15 (H) on prognosis of patients with LGG. (I) The correlation between expression of METTL21B and tumor mutation burden in LGG.